Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives

Ryo Naito, Takatoshi Kasai

Ryo Naito, Department of Cardiology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan
Takatoshi Kasai, Cardio-Respiratory Sleep Medicine, Department of Cardiology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan

Author contributions: All authors contributed equally to this editorial.
Conflict-of-interest: All of the authors declare no conflicts of interest related to this work.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Takatoshi Kasai, MD, Cardio-Respiratory Sleep Medicine, Department of Cardiology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan. kasai-t@mx6.nisiq.net Telephone: +81-3-38133111 Fax: +81-3-56890627 Received: December 3, 2014 Peer-review started: December 4, 2014 First decision: December 12, 2014 Revised: December 24, 2014 Accepted: January 15, 2015 Article in press: January 19, 2015 Published online: March 26, 2015

Abstract

Patients with type 2 diabetes mellitus (T2DM) are at a higher risk of developing coronary artery disease (CAD) than are non-T2DM patients. Moreover, the clinical outcomes in CAD with T2DM are poor despite improvements in medications and other interventions. Coronary artery bypass grafting is superior to percutaneous coronary intervention in treating multivessel coronary artery disease in diabetic patients. However, selecting a revascularization strategy depends not only on the lesion complexity but also on the patient’s medical history and comorbidities. Additionally, comprehensive risk management with medical and non-pharmacological therapies is important, as is confirmation regarding whether the risk-management strategies are being appropriately achieved. Furthermore, non-pharmacological interventions using exercise and diet during the earlier stages of glucose metabolism abnormalities, such as impaired glucose tolerance, might be beneficial in preventing the development or progression of T2DM and in reducing the occurrence of cardiovascular events.

Key words: Diabetes; Comprehensive risk management; Multivessel disease; Drug-eluting stents; Percutaneous coronary intervention

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Clinical outcomes in coronary artery disease with type 2 diabetes mellitus (T2DM) are poor despite improvements in medications and other interventions. Although coronary artery bypass grafting is superior to percutaneous coronary intervention in multivessel coronary artery disease with T2DM, selecting the revascularization strategy depends not only on the lesion complexity but also on the patient’s medical history and comorbidities. In these patients, comprehensive risk management with medical and non-pharmacological therapies is indispensable, and confirming whether such risk management is being appropriately achieved is also important. Furthermore, interventions with exercise and diet therapy during the early stages of glucose abnormalities might be effective in preventing the development or progression of T2DM and in reducing the occurrence of cardiovascular events.
INTRODUCTION

Patients with type 2 diabetes mellitus (T2DM) have a higher risk of developing coronary artery disease (CAD) than do patients without T2DM[1]. Additionally, 75% of T2DM patients die as a consequence of cardiovascular diseases, including CAD[2]. In patients with T2DM, CAD tends to be a more complex disease characterized by small, diffuse, calcified, multivessel involvement [multivessel disease (MVD)] and often requires coronary revascularization in addition to optimal medical therapy to control angina[5]. Regarding coronary revascularization, recent advances in the techniques and devices used during percutaneous coronary intervention (PCI) have expanded the indication of PCI to more complex lesions[6-8]. In particular, drug-eluting stents (DES) have reduced the restenosis and repeat revascularization rates[9,10]. However, the morbidity and mortality of CAD in patients with T2DM continues to be high, even in the current DES era[11]. Although most clinical trials comparing outcomes among T2DM patients with MVD have shown that coronary artery bypass grafting (CABG) was superior to PCI in terms of repeat revascularization and the incidence of myocardial infarction and mortality[12-17] (Table 1), it is not feasible to perform CABG in all diabetic patients with MVD. Because CABG is highly invasive in contrast to PCI, selecting a revascularization therapy depends not only on the lesion complexity but also on a patient's medical history and comorbidities. SYNTAX score is a reliable score to assess coronary anatomical features and lesion complexity[16]. EuroSCORE is also a useful scoring system that is based on the clinical background information of an individual patient, which might predict the operative mortality for patients undergoing cardiac surgery[18]. Recently, revised versions of these two scoring systems were proposed. Because combining the SYNTAX score and other clinical variables have been demonstrated to be more accurate in identifying the risk of patients with complex CAD compared with the SYNTAX score alone, the SYNTAX score II was constructed, which included the original SYNTAX score and the following variables: the presence of unprotected left main CAD, female gender, chronic obstructive pulmonary disease, age and left ventricular ejection fraction[19]. Similarly, EuroSCORE II is an updated version of the original EuroSCORE, reconstructed from a large database of 22381 consecutive patients undergoing cardiac surgery in 43 countries in 2010 using a logistic regression model[20]. These scoring systems may provide additional and reliable information to better decide revascularization strategies. In clinical trials, higher-risk surgical patients, such as the elderly and those with more comorbid diseases, have been excluded. Therefore, selecting a revascularization therapy for CAD with T2DM requires a thorough discussion of the patient's coronary anatomical features and lesion characteristics, age, and comorbid conditions.

Considering this issue, several important and as yet unresolved questions are raised including the following: (1) whether the newer DES are superior or similar in terms of repeat revascularization, incidence of myocardial infarction and mortality; (2) what can be done in conjunction with optimal medical and revascularization therapy to improve patient outcomes; and (3) whether early detection and intervention for CAD patients with undiagnosed T2DM or impaired glucose tolerance may improve mortality. In this editorial, we aim to provide novel insights into each of these specific questions and to consider the directions for future research.

REVASCULARIZATION THERAPY-
THE POTENTIAL OF NEWER DRUG-
ELUTING STENTS AND BIORESORBABLE
VASCULAR SCAFFOLDS

First, it is essential to understand what types of outcome measures were used in clinical trials to evaluate the effectiveness of a given revascularization strategy or to determine the superiority of one revascularization therapy over another. Clinical trials for cardiovascular diseases often use a composite assessment of major adverse cardiovascular events as outcome measures including all-cause mortality, myocardial infarction, stroke and repeat revascularization. Because death and myocardial infarction are considered to be hard and preferably primary endpoints, whereas repeat revascularization is a less hard and secondary endpoint according to the severity of each case, the primary and secondary endpoints should be treated as two distinct endpoints.

Advances in PCI have prompted the selection of this procedure in more complex lesions that previously had been indicated for CABG. However, MVD in T2DM patients is associated with a high incidence of repeat revascularization after PCI with DES; therefore, CABG remains superior to PCI in such lesions. A meta-analysis has demonstrated that the superiority of CABG to PCI with balloon angioplasty or bare metal stents in terms of all-cause mortality was greater in patients with than without T2DM[21].

To date, several clinical trials have been conducted at 85 centers in the United States and Europe to compare CABG and PCI with DES. The SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) was a prospective randomized trial that compared the efficacy of CABG and PCI with paclitaxel-eluting stents (PES) for patients with de-novo left main
coronary disease, three-vessel disease or both, which were considered equally suitable for CABG or PCI by both a cardiac surgeon and an interventional cardiologist at each center[22]. In the trial, 452 (25.1%) of the study population patients were diabetic, and these patients were included in a pre-specified sub-analysis. For 3-year major adverse cardiac and cerebrovascular events in the diabetic cohort, the incidence was 37.0% in the PCI group and 22.9% in the CABG group (P = 0.002). The rate of revascularization was also higher in the PCI group (PCI, 28.0% and CABG, 12.9%, P < 0.001)[23]. In 2012, a large-scale randomized trial known as the future revascularization evaluation in patients with diabetes mellitus (FREEDOM) trial was conducted. A total of 1900 diabetic patients with MVD were randomly assigned to CABG or to PCI with mainly sirolimus-eluting stents (SES) and PES[17]. The incidence of all-cause mortality and myocardial infarction was significantly lower in the CABG group during the mean follow-up period of 5 years compared with the DES group (CABG, 18.7% vs DES, 26.6%). Based on these results, the latest guidelines from the European Cardiology Society for the management of T2DM patients stated that PCI for MVD was a Class IIb indication for relieving symptoms as an alternative to CABG in patients with low SYNTAX scores[24]. However, in the FREEDOM trial, almost all patients in the PCI group were treated with first-generation DES that were replaced by new-generation DES used in current clinical practice. The newer generation DES have overcome the critical issue of stent thrombosis; in particular, the everolimus-eluting stent (EES) reduced myocardial infarction and stent thrombosis compared with other DES in a meta-analysis[25]. Recently, Bangalore and colleagues reported a meta-analysis of 68 randomized clinical trials to compare clinical outcomes in CAD patients with T2DM between those who received CABG and DES, including SES, PES and EES[26]. All-cause mortality was higher in the patients who received SES and PES compared with CABG, whereas the mortality rates in the EES group were similar to those of the CABG group (reference rate ratio to CABG, 1.31, 95%CI: 0.74-2.29). These results should be carefully interpreted because they were generated from an indirect comparison of individual clinical trials. Ongoing randomized trials in evaluation of the Xience Prime or Xience V stents vs coronary artery bypass surgery for the effectiveness of left main revascularization (EXCEL) and bypass surgery vs everolimus-eluting stent implantation for approaching multivessel disease (BEST) aim to determine the effectiveness of EES. EXCEL is a randomized trial comparing EES and CABG in patients with left main trunk lesions and SYNTAX scores of 32 or less. The BEST trial aims to compare EES and CABG in MVD. In both trials, a sub-analysis for diabetic patients is intended.

Regarding other novel devices, bioresorbable vascular scaffolds (BVS) may be a candidate treatment of CAD in diabetic patients. BVS are novel intracoronary devices that have potential advantages over metallic DES in terms of adverse coronary events such as stent thrombosis because unlike metallic DES, no uncovered struts or polymers exist after the scaffolds are resorbed[27]. To date, only a single clinical study has reported on the efficacy of BVS in diabetic patients. Muramatsu et al.[27] compared BVS and EES in diabetic patients using different clinical trials of each device and reported that the incidence of the clinical outcome, which was a composite of cardiac death, target vessel MI, or ischemia-driven target lesion revascularization, was similar between BVS and EES in diabetic patients (3.9% for the BVS vs 5.4% for EES, P = 0.38)[28].

Table 1: Clinical trials of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients

| Trial | Type of trial years of recruitment | Number of study population | Type of PCI | Endpoint | Main results (PCI vs CABG) |
|-------|----------------------------------|-----------------------------|-------------|----------|---------------------------|
| ARTS I [21] | Randomized 1997-1998 | 208 | BMS | 1 yr freedom from death, stroke, MI 63.4% vs 84.4% (P < 0.001) or revascularization | |
| MASS II [22] | Randomized 1995-2000 | 115 | N/A | 1 yr death | 5.3% vs 6.8% (P = 0.5) |
| BARI-2D [23] | Randomized 2001-2005 | 1605 | 1° DES: 34.7% | 5 yr freedom from death, MI, repeat revascularization | PCI vs medical (77.0 vs 78.9; P = 0.15) |
| Comparison between revascularization and medical 2000-2005 | | | BMS: 56.0% | | CABG vs medical (77.6 vs 69.5%; P = 0.01) |
| CARDia [24] | Randomized 2002-2007 | 510 | Others: 9.3% | 1 yr death, stroke, or MI | P for interaction 0.002 |
| SYNTAX [25] | Randomized 2005-2007 | 452 | 1° DES | 5 yr death, stroke, MI, or revascularization | 46.5% vs 29.0% (P < 0.001) |
| FREEDOM [26] | Randomized 2005-2010 | 1900 | 1° DES | 5 yr death | 16.3% vs 10.9% (P = 0.049) |
| | | | 5 yr death, nonfatal MI, or nonfatal stroke | 26.6% vs 18.7% (P = 0.005) |

PCI: Percutaneous coronary intervention; CABG: Coronary artery bypass grafting; DES: Drug-eluting stent; ARTS: Arterial revascularization Therapies Study; BMS: Bare metal stent; MACE: Major adverse cardiovascular event; MI: Myocardial infarction; MASS: Medicine, Angioplasty, or Surgery Study; 1° DES: First generation DES.
As described by the authors, the data analysis was performed using different pooled data and the study population number was quite small (n = 102 in the BVS group and 172 in the EES group). Further studies in a larger cohort of diabetic patients are required to demonstrate the safety and efficacy of BVS.

COMPREHENSIVE RISK MANAGEMENT AND INTERVENTIONS

Because clinical outcomes in T2DM patients with CAD are poor, aggressive medical and non-pharmacological therapies are indispensable, regardless of the revascularization strategy pursued. The bypass angioplasty revascularization investigation in type 2 diabetes (BARI-2D) trial examined and compared long-term clinical outcomes between medical therapy alone and revascularization by PCI or CABG in T2DM patients. No significant difference was observed between the PCI and CABG groups in all-cause mortality or in the event-free survival rates for cardiovascular events during the 5-year follow-up period. These data indicated the importance of comprehensive risk management with glycemic control and the administration of statins, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, and antiplatelet therapy in T2DM patients with CAD. Guidelines for the management of diabetes mellitus from the American Diabetes Association, the American College of Cardiology and the American Heart Association recommend the following prevention strategies for CAD: blood pressure 130/80 mmHg or less, low-density lipoprotein cholesterol (LDL-C) below 100 mg/dL (below 70 mg/dL for CAD patients) and prompt smoking cessation. However, a previous study examining the achievement of risk management in the large-scale clinical trials of clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE), BARI-2D and FREEDOM, showed unexpectedly low achievement rates. One-year risk management achievement rates (LDL-C < 100 mg/dL (70 mg/dL in the FREEDOM trial), systolic blood pressure < 130 mmHg, glycated hemoglobin < 7.0% and smoking cessation) were 18%, 23% and 8% in the COURAGE, BARI-2D and FREEDOM trials, respectively. Although the achievement rate was not originally included in the clinical trial endpoints, these results prompted us to review our clinical practices regarding not only adherence to evidence-based medical therapy but also whether risk management is being properly achieved. Furthermore, non-pharmacotherapeutic strategies including exercise, diet and smoking cessation should be pursued.

INTERVENTIONS FOR IMPAIRED GLUCOSE TOLERANCE

Considering that patients with T2DM tend to have macro- and microvascular complications and that the clinical outcomes of CAD patients are poor, interventions are desirable during the earlier stages of T2DM, such as impaired glucose tolerance (IGT). We understand that IGT is not simply an early stage of T2DM but rather an important state predisposing to T2DM. In fact, progression to diabetes was observed in 10% of IGT patients. Additionally, it was suggested that IGT itself might have an impact on CAD morbidity and mortality. However, it is not fully elucidated whether IGT in CAD patients might be a treatment target for secondary prevention the effects of anti-diabetic agents on reducing progression to diabetes or the incidence of cardiovascular events in such patients. Nevertheless, non-pharmacological therapies such as nutrition and exercise are important even in IGT patients. Previous studies reported that about one-third of CAD patients who had not been diagnosed with diabetes were actually diabetic. Thus, aggressive evaluation for diabetes and IGT are required in CAD patients. In current clinical practice, although fasting blood glucose and glycated hemoglobin diabetes testing is routinely performed, the glucose tolerance test is not frequently performed in CAD patients unless the fasting blood glucose or glycated hemoglobin levels are above the upper limits of normal. To detect diabetes at an earlier stage, blood glucose, glycated hemoglobin and glucose tolerance tests for diabetes are considerably important.

CONCLUSION

When selecting revascularization strategies in diabetic patients, physicians must thoroughly consider not only a patient’s coronary artery lesions but also his/her medical history. Additionally, comprehensive risk management with medical and non-pharmacological therapies should be performed and the proper achievement of risk management should be confirmed. Furthermore, non-pharmacological interventions through exercise and diet therapy during the earlier stages of glucose metabolism abnormalities such as IGT may also be beneficial in preventing the development or progression of T2DM and in reducing the occurrence of cardiovascular events by either primary or secondary prevention of CAD.

REFERENCES

1. Center for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the US 2011. Washington, DC: US Department of Health and Human Services, 2011

2. Hammond T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36: 355-365 [PMID: 10933343 DOI: 10.1016/S0735-1097(00)00732-4]

3. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Rydén L, Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
Moor MH, Morice MC, Kappetein AP, Feldman TE, Stähle E, Colombo A, Mack MJ, Holmes DR, Morel MA, Van Dyck N, Hoult VM, Dawkins KD, Serruys PW, Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 2013; **381**: 629-638 [DOI: 10.1016/S0140-6736(13)60141-5]

Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dansag G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhangava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S, Bertrand M, Faster V. Strategies for multivessel revascularization in patients with diabetes. *N Engl J Med* 2012; **367**: 2375-2384 [DOI: 10.1056/NEJMoa1211585]

Nashef SA, Roques F, Michel P, Gauducheau E, Lemesnow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). *Europ J Cardiothorac Surg* 1999; **16**: 9-13 [DOI: 10.1016/S1010-7940(99)00134-7]

Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, Kappetein AP, Colombo A, Holmes DR, Mack M, Feldman T, Morice MC, Stähle E, Onuma Y, Morel MA, Garcia-Garcia HM, van ES GA, Dawkins KD, Mohr FW, Serruys PW. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet* 2013; **381**: 639-650 [DOI: 10.1016/S0140-6736(13)60108-7]

Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, Lockwood VA. EuroSCORE II. *Europ J Cardiothorac Surg* 2011; **41**: 734-744; discussion 744-745 [DOI: 10.1016/j.ejcts.2010043]

Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carridi D, Clayton TC, Danchin N, Fletter M, Hamm CW, Hueb WA, Kühler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Poeck SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009; **373**: 1190-1197 [DOI: 19303634]

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Stähle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW. Percutaneous coronary intervention versus coronary artery bypass grafting for severe coronary artery disease. *N Engl J Med* 2009; **360**: 961-972 [DOI: 10.1056/NEJMoa0804626]

Mack MJ, Banning AP, Serruys PW, Morice MC, Taeymans Y, Van Nooten G, Possati G, Crea F, Hooft KL, Leadley K, Dawkins KD, Kappetein AP. Bypass versus drug-eluting stents at three years in patients with diabetes mellitus or metabolic syndrome. *Ann Thorac Surg* 2011; **92**: 2140-2146 [DOI: 10.1016/j.atvs.2011.06.028]

Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huiukri H, Marre M, Mars N, Mellbin L, Ostergren J, Patruno C, Scherillo P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, Zamorano JM, Achenbach S, Baugartner H, Bas JX, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Hasdai D, Hoes AW, Kirchhof P, Lévy E, Melchiorre C, Nashef SA, Piepoli MF, Ponikowski P, Sirnes PA, Torbicki A, Tendera M, Tuomilehto J, Valsangiacomo P, Zamorano JL, Zamorano JM. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. *Atheroscler Suppl* 2010; **11**: e1-e162 [DOI: 10.1016/j.athoracsur.2006.08.050]

Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, Mac Gregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Moltchke ME, Nestle RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009; **360**: 2503-2515 [DOI: 19502645]

Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Naicker S, O'Riordan T, Orchard TJ, Genuth SM, Goldberg SH, Frye RL. Type 2 Diabetes and Cardiac and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy. *Part I. Circulation* 2003; **108**: 1527-1532 [DOI: 14504252]

Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004; **350**: 221-231 [DOI: 14724301]

Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostazadeh J, Cao S, Simonton CA, Sudhir K, Lanksy AJ, Cutlip DE, Kereiakes DJ, Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med* 2010; **362**: 1663-1674 [DOI: 20445180]

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kurtz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med* 2003; **349**: 1315-1323 [DOI: 14523139]

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schulter G, Barragan P, Guariguati G, Molnár F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002; **346**: 1773-1780 [DOI: 12050336]

Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of clinical trials of drug-eluting stents. *Lancet* 2004; **364**: 583-591 [DOI: 15313358]

Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Williams DO, Slater J, Cutlip DE, Felt F. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. *BMJ* 2012; **345**: e5170 [DOI: 22885395]

Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Serruys PW, Sousa AG, Sousa JE, van Hout B, Hugenholdt PG, Unger F, Serruys PW. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. *Circulation* 2001; **104**: 533-538 [DOI: 11479249]

Hueb W, Gersh BJ, Costa F, Lopes N, Soares PR, Dutra P, Jatene F, Pereira AC, Góis AF, Oliveira SA, Ramires JA. Impact of diabetes on five-year outcomes of patients with multivessel coronary artery disease. *Ann Thorac Surg* 2007; **83**: 93-99 [DOI: 17184637]

Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, Mac Gregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Moltchke ME, Nestle RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N Engl J Med* 2009; **360**: 2503-2515 [DOI: 19502645]

Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJ. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. *J Am Coll Cardiol* 2010; **55**: 432-440 [DOI: 20117456]
developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087 [PMID: 23996285]

25 Baber U, Mehran R, Sharma SK, Brar S, Yu J, Suh JW, Kim HS, Park SJ, Kastrati A, de Waha A, Krishnan P, Moreno P, Sweeney J, Kim MC, Suleman J, Pyo R, Wiley J, Kovac J, Kini AS, Dangas GD. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58: 1569-1577 [PMID: 21924575 DOI: 10.1016/j.jacc.2011.06.049]

26 Bangalore S, Toklu B, Feit F. Response to letter regarding article, “Outcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: can newer generation drug-eluting stents bridge the gap?”. Circ Cardiovasc Interv 2014; 7: 729 [PMID: 25336609 DOI: 10.1161/CIRCINTERVENTIONS.114.001970]

27 Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, Diletti R, Garcia-Garcia HM, Dorange CC, Veldhof S, Cheong WF, Ozaki Y, Whitbourn R, Bartorelli A, Stone GW, Alzibaad A, Serruys PW. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv 2014; 7: 482-493 [PMID: 24746560 DOI: 10.1016/j.jcin.2014.01.155]

28 Onuma Y, Serruys PW. Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization? Circulation 2011; 123: 779-797 [PMID: 21343594 DOI: 10.1161/CIRCULATIONAHA.110.971666]

29 American Diabetes Association. Executive summary: Standards of medical care in diabetes-2012. Diabetes Care 2012; 35 Suppl 1: S4-S10

30 Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hirtzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-2473 [PMID: 22652934 DOI: 10.1161/CIR.0b013e3182325e9b]

31 Skyler JS, Bergenstal R, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298-304 [PMID: 19147051 DOI: 10.1016/j.jacc.2008.10.008]

32 Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogedie M, Bertolet M, Mathewkuty S, Teo K, Maron DJ, Seh, Domanski M, Frye RL, Fuster V. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013; 61: 1607-1615 [PMID: 23500281 DOI: 10.1016/j.jacc.2013.01.044]

33 Goldline AB, Phua EJ, Abrahamson MJ. Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation 2012; 127: 2567-2573 [PMID: 24934644 DOI: 10.1161/CIRCULATIONAHA.113.006634]

34 Huang Y, Cai X, Chen P, Mai W, Tang H, Huang Y, Hu Y. Associations of prediabetes with all-cause and cardiovascular mortality: A meta-analysis. Ann Med 2014; 46: 684-692 [PMID: 25230915 DOI: 10.3109/07853890.2014.955051]

35 Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Hata T, Nakama Y, Kijima Y, Kagawa E. Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur Heart J 2006; 27: 2413-2419 [PMID: 17000629 DOI: 10.1093/eurheartj/ehl271]

36 Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Rydén L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140-2144 [PMID: 12090978 DOI: 10.1016/S0140-6736(02)09089-X]
